Sugar-free, glycine-stabilized intravenous immunoglobulin prevents skin but not renal disease in the MRL/lpr mouse model of systemic lupus

Lupus

Volumn 19, Issue 5, 2010, Pages 599-612

  Racz, Z ^a   Nagy, E ^a   Rosivall, L ^a   Szebeni, J ^a,b   Hamar, P ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b SeroScience Ltd   (Hungary)

Author keywords

Complement; Intravenous immunoglobulin; Lupus nephritis; Osmotic nephrosis; Skin; Systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; DNA ANTIBODY; GLYCINE; IMMUNOGLOBULIN; MALTOSE; NITROGEN; SM ANTIBODY; SUCROSE; UREA;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SPECIFICITY; DRUG STABILITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZATION; KIDNEY FUNCTION; KIDNEY TUBULE DAMAGE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SKIN DEFECT; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; DISEASE MODELS, ANIMAL; GLYCINE; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED MRL LPR; SKIN DISEASES;

EID: 77951228471     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309355299     Document Type: Article

References (78)

1. Danchenko N., Satia JA, Anthony MS Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006 ; 15: 308-318. (Pubitemid 43828810)
2. Holers VM Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J Clin Invest 2004 ; 114: 616-619. (Pubitemid 39578750)
3. Kökény G., Godó M., Nagy E., et al. Skin disease is prevented but nephritis is accelerated by multiple pregnancies in autoimmune MRL/LPR mice. Lupus 2007 ; 16: 465-477. (Pubitemid 47242519)
4. Nicoletti F., Di Marco R., Zaccone P., et al. Dichotomic effects of IFN-g on the development of systemic lupus erythematosus-like syndrome in MRL-lpr/lpr mice. Eur J Immunol 2000 ; 30: 438-447. (Pubitemid 30098836)
5. Tokano Y., Morimoto S., Amano HM, et al. The relationship between initial clinical manifestation and long-term prognosis of patients with systemic lupus erythematosus. Mod Rheumatol 2005 ; 15: 275-282. (Pubitemid 41236276)
6. Theofilopoulos AN, Dixon FJ Immune complexes in human diseases. Am J Pathol 1980 ; 100: 529-594.
7. Pizarro S., Monárrez Espino J., Ruiz A., et al. Soluble vascular cell adhesion molecule-1 indicates SLE disease activity and specific organ involvement. Rev Alerg Mex 2007 ; 54: 189-195.
8. Tesar V., Masek Z., Rychlik I., et al. Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 1998 ; 13: 1662-1667. (Pubitemid 28306791)
9. Frijns R., Fijnheer R., Schiel A., et al. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J Rheum 2001 ; 28: 514-519. (Pubitemid 32202652)
10. Harari OA, Marshall D., McHale JF, et al. Limited endothelial E- and P-selectin expression in MRL/lpr lupus-prone mice. Rheum 2001 ; 40: 889-895. (Pubitemid 32816060)
11. Rubinstein T., Pitashiny M., Putterman C. The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/Lipocalin-2 as a biomarker for lupus nephritis. Autoimmun Rev 2008 ; 3: 229-234.
12. Yang JQ, Saxena V., Xu H., et al. Repeated α-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol 2003 ; 171: 4439-4446. (Pubitemid 37238724)
13. Carlsten H., Nilsson N., Jonsson R., et al. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL6lpr mice. Cell Immunol 1992 ; 144: 190-202.
14. Yokoyama H., Kreft B., Kelley VR Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with a differing regulatory mechanism. Kid Internat 1995 ; 47: 122-130.
15. Kikawada E., Lenda DM, Kelley VR IL-12 deficiency in MRL-Faslpr mice delays nephritis and intrarenal IFN-γ expression, and diminisches systemic pathology. J Immunol 2003 ; 170: 3915-3925. (Pubitemid 36359263)
16. Mitchell DA, Pickering MC, Warren J., et al. C1q deficiency and autoimmunity: the effects o genetic background on disease expression. J Immunol 2002 ; 37: 111-123. (Pubitemid 34171862)
17. Yang JQ, Chun T., Liu H., et al. CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol 2004 ; 34: 1723-1732. (Pubitemid 39256055)
18. Chan OT, Paliwal V., McNiff JM, et al. Deficiency in beta(2)- microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Fas(lpr) nice: an example of disease regulation at the organ level. J Immunol 2001 ; 167: 2985-2990. (Pubitemid 32768936)
19. Wuthrich RP, Yui MA, Mazoujian G., et al. Enhanced MHC class II (reactive with CD4 T-cells) expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritis. Am J Pathol 1989 ; 134: 45-51. (Pubitemid 19054977)
20. Suzuka H., Yoshifusa H., Nakamura Y., et al. Morphological analysis of autoimmune disease in MRL-lpr, Yaa male mice with rapidly progressive systemic lupus erythematosus. Autoimmunity 1993 ; 14: 275-282. (Pubitemid 23214052)
21. DCruz DP, Hughes GRV. The treatment of lupus nephritis. BMJ 2005 ; 330: 377-378.
22. Kaveri SV, Dietrich G., Hurez V., Kazatchkine MD Intravenuous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 1990 ; 86: 192-198.
23. Mouthon L., Kaveri SV, Spalter SH, et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin Exp Immunol 1996 ; 104: S3 - S9. (Pubitemid 26140277)
24. Generau T., Chosidow O., Danel C., et al. High-dose intravenous immunglobulin in cutaneous lupus erythematosus. Arch Dermatol 1999 ; 135: 1124-1125. (Pubitemid 29430512)
25. Winder A., Molad Y., Ostfeld I., et al. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 1993 ; 3: 495-498. (Pubitemid 23102474)
26. Levy Y., Sherer Y., Ahmed A., et al. A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus 1999 ; 8: 705-712.
27. Corvetta A., Della Bitta R., Gabrielli A., et al. Use of high-dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases. Clin Exp Rheumatol 1989 ; 3: 295-299. (Pubitemid 19200339)
28. Lafferty TE, Smith JB, Schuster SJ, et al. Treatment of acquired factor VIII inhibitor using intravenous immunoglobulin in two patients with systemic lupus erythematosus. Arthritis Rheum 1997 ; 4: 775-778. (Pubitemid 27157586)
29. Sherer Y., Levy Y., Langevitz P., et al. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 1999 ; 18: 170-173. (Pubitemid 29223043)
30. Boletis JN, Ioannidis JPA, Boki KA, et al. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. The Lancet 1999 ; 354: 569-570.
31. Lin CY, Hsu HC, Chiang H. Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin. Nephron 1989 ; 53: 303-310. (Pubitemid 19267243)
32. Tan E., Hajinazarian M., Bay W., et al. Acute renal failure resulting from intravenous immunolgobulin therapy. Arch Neurol 1993 ; 50: 137-139. (Pubitemid 23054794)
33. Monova D., Belovezhdov N., Altunkova I., et al. Intravenous immunoglobulin G in the treatment of pateints with chronic glomeruloneohritis: clinical experience lasting 15 years. Nephron 2002 ; 90: 262-266. (Pubitemid 34195752)
34. Orbach H., Tishler M., Shoenfeld Y. Intravenous immunoglobulin and the kidney-a two-edged sword. Sem Arthritis Rheum 2004 ; 34: 593-601. (Pubitemid 39643121)
35. Barton JC, Herrera GA, Galla JH, et al. Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. Am J Med 1987 ; 82: 624-629.
36. Wajanaponsan N., Cheng SF Acute renal failure resulting from intravenous immunoglobulin therapy. Hawaii Med J 2004 ; 63: 266-267.
37. Sati HIA, Ahya R., Watson HG Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol 2001 ; 113: 556-557. (Pubitemid 32523170)
38. Fakhouri F. Intravenous immunoglobulins and acute renal failure: mechanism and prevention. Rev Med Interne 2007 ; 28: 4-6.
39. Allen AC (ed.), The kidney. Medical and surgical diseases. New York: Grune and Stratton; 1951.
40. Cantu TG, Hoehn-Saric EW, Burgess KM, et al. Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 1995 ; 2: 228-234.
41. Ahsan N., Wiegand LA, Abendroth CS, et al. Acute renal failure following immunglobulin therapy. Am J Nephrol 1996 ; 16: 532-536. (Pubitemid 26387941)
42. Haskin JA, Warner DJ, Blank DU Acute renal failure after large doses of intravenous immune globulin. Ann Pharmacother 1999 ; 33: 800-803. (Pubitemid 29387658)
43. Szenczi Á., Kardos J., Medgyesi GyA, et al. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution. Biologicals 2005 ; 34: 5-14. (Pubitemid 43295413)
44. Vo AA, Cam V., Toyoda M., et al. Safety and adverse events profiles of intravenuous gammaglobulin products used for immunomodulation: a single-center experience. Clin J Am Soc Nephrol 2006 ; 1: 844-852.
45. Chapman SA, Pham D. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother 2004 ; 38: 2059-2067.
46. Hansen-Schmidt S., Silomon J., Keller F. Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis. Am J Kidney Dis 1996 ; 3: 451-453. (Pubitemid 26304427)
47. Cohen PL, Eisenberg RA Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991 ; 9: 243-269.
48. Pisetsky DS, McCarty GA, Peters DV Mechanisms of autoantibody production in autoimmune MRL mice. J Exp Med 1980 ; 152: 1302-1310.
49. Kolaja GJ, Fast PE Renal lesions in MRL mice. Vet Pathol 1982 ; 19: 663-668.
50. Diaz GC, Jevnikar AM, Brenan DC, et al. Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. Kidney Int 1992 ; 42: 851-859.
51. Kanauchi H., Furukawa F., Imamura S. Characterization of cutaneous infiltrates in MRL/lpr mice monitored from onset to the full development of lupus erythematosus-like skin lesions. J Invest Dermatol 1991 ; 96: 478-483.
52. Furukawa F., Tanaka H., Sekita K., et al. Dermatopathological studies on skin lesions of MRL mice. Arch Dermatol Res 1984 ; 276: 186-194. (Pubitemid 14107771)
53. Gürcan HM, Ahmed AR Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother 2007 ; 5: 812-823.
54. Ruetter A., Ludger TA Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol 2004 ; 5: 153-160. (Pubitemid 38901544)
55. Medlin Plus. Immune Globulin Intravenous Injection. http://www.nlm.nih. gov/medlineplus/druginfo/meds/a682815.html (Last accessed on 16 June 2009 and 18 Nov 2009 )
56. Gaedicke G., Telle WM, Kohne E., et al. IgG therapy in systemic lupus erythematosus. Annals of Hematology 1984 ; 48: 387-390.
57. Ballow M., Parke A. The uses of intavenous immune globuline in collagen vascular disorders. J Allergy Clin Immunol 1989 ; 84: 608-612. (Pubitemid 19266758)
58. Kaneko Y., Nimmerjahn F., Madaio MP, Ravetch JV Pethology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. JEM 2006 ; 203: 789-797.
59. Chacko B., John GT, Balakrishnan N., Kirubakaran MG, Jacob CK Osmotic nephropathy resulting from maltose-based intravenous immunoglobulin therapy. Ren Fail 2006 ; 28: 193-195.
60. Metallidis S., Papaioannu M., Bokolas G., Kollaras P., Gogou V., Nikolaidis P. Acute renal failure following intravenous immunoglobulin therapy in HIV-infected patient. Clin Nephrol 2009 ; 71: 196-197.
61. Ullman S., Halberg P., Wolf-Jürgensen P. Deposits of immunoglobulins and complement C3 in clinically normal skin of patients with lupus erythematosus. Acta Derm Venereol 1975 ; 55: 109-112.
62. Alexander JJ, Bao L., Jacob A., et al. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim Biophys Acta 2003 ; 1639: 169-176. (Pubitemid 37421424)
63. Zabaleta-Lanz ME, Munoz LE, Tapanes FJ, et al. Further description of early clinically silent lupus nephritis. Lupus 2006 ; 15: 845-851.
64. Watanabe H., Garnier G., Circolo A., et al. Modulation of renal disease in MRL/lpr mice genetically deficient int he alternative complement pathway factor B. J Immunol 2000 ; 164: 786-794. (Pubitemid 30043702)
65. Ito MR, Terasaki S., Kondo E., et al. Experimental lupus nephritis is severe combined immunodeficient (SCID) mice: remodelling of the glomerular lesions by bystander IgM antibodies. Clin Exp Immunol 2000 ; 119: 340-345. (Pubitemid 30073040)
66. Nakatani K., Fujii H., Hasegawa H., et al. Endothelial adhesion molecules in glomerular lesions: association with their severity and diversity in lupus models. Kidney Int 2004 ; 65: 1290-1300. (Pubitemid 38406967)
67. Itoh J., Nose M., Takahashi S., et al. Induction of different types of glomerulonephritis by monoclonal antibodies derived from an MRL/lpr lupus mouse. Am J Pathol 1993 ; 143: 1436-1443. (Pubitemid 124000659)
68. Sekine H., Reilly CM, Molano ID, et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001 ; 166: 6444-6451. (Pubitemid 32440780)
69. Bleeker WK, Teeling JL, Hack CE Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 2001 ; 98: 3136-3142.
70. Tomino Y., Sakai H., Takaya M., Suga T., Endoh M., Nomoto Y. Solubilization of intraglomerular deposits of IgG immune complexes by human sera or gamma-globulin in patients with lupus nephritis. Clin Exp Immunol 1984 ; 58: 42-48. (Pubitemid 14029122)
71. Blank M., Manosroi J., Tomer Y., et al. Suppression of experimental systemic lupus erythematosus (SLE) with specific anti-idiotypicantibody-saporin conjugate. Clin Exp Immunol 1994 ; 98: 434-441. (Pubitemid 24374728)
72. Tomer Y., Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high-dose intravenous immunoglobulin. Clin Exp Rheumatol 1992 ; 10: 391-393.
73. Bakimer R., Gilburd B., Zurgil N., Shoenfeld Y. The effect of intravenous-γ-globulin on the induction of experimental antiphospholipid syndrome. Clin Exp Immunopathol 1993 ; 69: 97-102. (Pubitemid 23303582)
74. Basta M., Van Goor F., Luccioli S., et al. F(ab)2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003 ; 9: 431-438. (Pubitemid 36460077)
75. Berger M., Rosenkranz P., Brown CY Intravenous and standard immune serum globulin preparations interfere with uptake of 125 I-C3 onto sensitized erythrocytes and inhibit hemolytic complement activity. Clin Immunol Immunopathol 1985 ; 34: 227-236. (Pubitemid 15163040)
76. Wilmer HA The mechanism of sucrose damage of the kidney tubules. Am J Physiol 1944 ; 141: 431-438.
77. Chetterjee PK, Cuzzocrea S., Brown PAJ, et al. Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. Kidney Int 2000 ; 58: 658-673. (Pubitemid 30620015)
78. Girardi G., Berman J., Redecha P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003 ; 112: 1644-1654. (Pubitemid 38063722)